Rani Therapeutics Holdings, Inc. $RANI

What the company doesAI summary of filing

Rani Therapeutics is a clinical-stage biopharmaceutical company developing the RaniPill capsule, an oral delivery platform designed to deliver biologics such as antibodies, proteins, peptides, and oligonucleotides. The company has no approved products and has not generated revenue from commercial product sales. Rani is advancing multiple product candidates in clinical and preclinical development, including RT-114 (a GLP-1/GLP-2 dual agonist for obesity, which entered Phase 1 trials in December 2025), RT-116 (semaglutide for obesity), RT-111 (ustekinumab biosimilar for inflammatory conditions, which completed a Phase 1 study), and RT-105 (adalimumab biosimilar for inflammatory conditions, currently paused). The company also entered into a collaboration with Chugai Pharmaceutical in October 2025 for RT-117, combining Chugai's antibody with the RaniPill HC platform for hemophilia treatment, and received a $10 million upfront payment plus potential milestone and royalty payments. [10-K 2026-03-26]

Segments: RT-114 (GLP-1/GLP-2 dual agonist for obesity), RT-116 (semaglutide for obesity), RT-111 (ustekinumab biosimilar for inflammatory conditions), RT-105 (adalimumab biosimilar for inflammatory conditions)